← All drugs
Drug · FAERS side-effect profile with label screen

Praziquantel side effects: what 300 FDA adverse event reports show

Praziquantel · Biltricide · 7 reaction terms · 54 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Anthelmintic

FDA label (Established Pharmacologic Class) · compare the class

Brand names

Biltricide

openFDA label

Who reports

300 reports · 82% serious · 26 with death outcome · 43% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Biltricide is indicated in patients aged 1 year and older for the treatment of the following infections: • Schistosomiasis due to all species of schistosoma (for example, Schistosoma mekongi, Schistosoma japonicum, Schistosoma mansoni and Schistosoma h.

FDA label, Indications and Usage

What it is

Biltricide (praziquantel) is an anthelmintic, trematodicide provided in tablet form for oral administration. Praziquantel is 2-(cyclohexylcarbonyl)-1,2,3,6,7, 11b-hexahydro-4H-pyrazino [2, 1-a] isoquinolin-4-one with the molecular formula; C 19 H 24 N 2 O 2 .

FDA label, Description section

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 5 strongest signals

Labeled adverse reaction 1Reporting / coding artifact 2Not in label — unassessed 2
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 2 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Eosinophilia1351.9
30.5–88.3ROR 54.2 · χ² 599 / p 2e-132
48.4 EB05 30.1 · IC025 +3.2
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 38.1no trial data cached
Product prescribing issue1241.1
23.6–71.6ROR 42.8 · χ² 430 / p 7e-96
38.8 EB05 23.6 · IC025 +3.0
3/3 methods agree
Reporting / coding artifactserious PRR 6.3no trial data cached
Eyelid oedema529.8
12.5–71.0ROR 30.3 · χ² 112 / p 2e-26
25.5 EB05 9.4 · IC025 +1.5
3/3 methods agree
Not in label — unassessedserious PRR 30.6no trial data cached
Osteonecrosis (bone death)918.9
9.9–36.0ROR 19.5 · χ² 136 / p 1e-31
17.4 EB05 8.5 · IC025 +2.1
3/3 methods agree
Not in label — unassessedserious PRR 13.4no trial data cached
Drug exposure during pregnancy816.2
8.2–32.0ROR 16.6 · χ² 99 / p 1e-23
13.9 EB05 6.1 · IC025 +1.9
3/3 methods agree
Reporting / coding artifactserious PRR 12.6no trial data cached

Trial evidence (ClinicalTrials.gov)

Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Eosinophilia1351.9
30.5–88.3ROR 54.2 · χ² 599 / p 2e-132
48.4 EB05 30.1 · IC025 +3.2
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 38.1no trial data cached
Product prescribing issue1241.1
23.6–71.6ROR 42.8 · χ² 430 / p 7e-96
38.8 EB05 23.6 · IC025 +3.0
3/3 methods agree
Reporting / coding artifactserious PRR 6.3no trial data cached
Osteonecrosis (bone death)918.9
9.9–36.0ROR 19.5 · χ² 136 / p 1e-31
17.4 EB05 8.5 · IC025 +2.1
3/3 methods agree
Not in label — unassessedserious PRR 13.4no trial data cached
Drug exposure during pregnancy816.2
8.2–32.0ROR 16.6 · χ² 99 / p 1e-23
13.9 EB05 6.1 · IC025 +1.9
3/3 methods agree
Reporting / coding artifactserious PRR 12.6no trial data cached
Eyelid oedema529.8
12.5–71.0ROR 30.3 · χ² 112 / p 2e-26
25.5 EB05 9.4 · IC025 +1.5
3/3 methods agree
Not in label — unassessedserious PRR 30.6no trial data cached
Myelosuppression48.2
3.1–21.7ROR 8.3 · χ² 19 / p 8e-6
4.9 EB05 2.0 · IC025 +0.4
3/3 methods agree
Not in label — unassessedserious PRR 5.8no trial data cached
Hepatic cytolysis317.1
5.5–52.7ROR 17.3 · χ² 31 / p 1e-8
9.2 EB05 2.4 · IC025 +0.3
3/3 methods agree
Not in label — unassessedserious PRR 12.0no trial data cached

Unlabeled candidate signals

Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Praziquantel?

In FDA FAERS, the most frequently co-reported reaction terms for Praziquantel are eosinophilia, osteonecrosis, eyelid oedema, myelosuppression, hepatic cytolysis. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Praziquantel have an FDA boxed warning?

No. The FDA label retrieved for Praziquantel has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Praziquantel causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.